NCT07072884View on ClinicalTrials.gov

GC012F in Patients With Autoimmune Diseases

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions
Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)
Interventions
DRUG

GC012F injection

Subjects who meet the CAR-T cell infusion criteria will receive GC012F Injection infusion within 48-72 hours after completion of lymphodepleting preconditioning.

All Listed Sponsors
collaborator

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY

lead

Qiong Fu

OTHER